OraSure Technologies (NASDAQ:OSUR) has recently filed with the U.S. Food and Drug Administration (“FDA”) an application for a waiver under the Clinical Laboratory Improvement Amendments (“CLIA”) for its OraQuick hepatitis C (“HCV”) Rapid Antibody Test for use with venous and finger-stick whole blood samples. CLIA is the U.S. regulatory standard for all human clinical laboratory [...]